Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

November 01, 2005; Volume 33,Issue 11

Commentary

  • You have access
    IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?
    A. David Rodrigues
    Drug Metabolism and Disposition November 2005, 33 (11) 1567-1575; DOI: https://doi.org/10.1124/dmd.105.006452

Short Communications

  • You have access
    INTERACTION OF PROGESTINS WITH THE HUMAN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (MRP2)
    Heike Lindenmaier, Melanie Becker, Walter Emil Haefeli and Johanna Weiss
    Drug Metabolism and Disposition November 2005, 33 (11) 1576-1579; DOI: https://doi.org/10.1124/dmd.105.005314
  • You have access
    EXTRACTS AND KAVALACTONES OF PIPER METHYSTICUM G. FORST (KAVA-KAVA) INHIBIT P-GLYCOPROTEIN IN VITRO
    Johanna Weiss, Alexandra Sauer, Andreas Frank and Matthias Unger
    Drug Metabolism and Disposition November 2005, 33 (11) 1580-1583; DOI: https://doi.org/10.1124/dmd.105.005892
  • You have access
    MODULATION OF P-GLYCOPROTEIN EXPRESSION IN HYPERTHYROID RAT TISSUES
    Naoki Nishio, Toshiya Katsura, Kayoko Ashida, Masahiro Okuda and Ken-ichi Inui
    Drug Metabolism and Disposition November 2005, 33 (11) 1584-1587; DOI: https://doi.org/10.1124/dmd.105.004770
  • You have access
    ANTI-AIDS AGENTS 65: INVESTIGATION OF THE IN VITRO OXIDATIVE METABOLISM OF 3′,4′-DI-O-(–)-CAMPHANOYL-(+)-CIS-KHELLACTONE DERIVATIVES AS POTENT ANTI-HIV AGENTS
    Madoka Suzuki, Yutai Li, Philip C. Smith, James A. Swenberg, David E. Martin, Susan L. Morris-Natschke and Kuo-Hsiung Lee
    Drug Metabolism and Disposition November 2005, 33 (11) 1588-1592; DOI: https://doi.org/10.1124/dmd.105.004218
  • You have access
    DISPOSITION OF ORAL AND INTRAVENOUS PRAVASTATIN IN MRP2-DEFICIENT TR– RATS
    Kari T. Kivistö, Olaf Grisk, Ute Hofmann, Konrad Meissner, Klaus-Uwe Möritz, Christoph Ritter, Katja A. Arnold, Dieter Lutjöohann, Klaus von Bergmann, Ingrid Klöting, Michel Eichelbaum and Heyo K. Kroemer
    Drug Metabolism and Disposition November 2005, 33 (11) 1593-1596; DOI: https://doi.org/10.1124/dmd.105.006262
  • You have access
    ESTROUS CYCLE ALTERS NAPHTHALENE METABOLISM IN FEMALE MOUSE AIRWAYS
    Rhonda L. Stelck, Gregory L. Baker, Katherine M. Sutherland and Laura S. Van Winkle
    Drug Metabolism and Disposition November 2005, 33 (11) 1597-1602; DOI: https://doi.org/10.1124/dmd.105.005124
  • You have access
    LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE
    May Fakhoury, Catherine Litalien, Yves Medard, Hélène Cavé, Nadia Ezzahir, Michel Peuchmaur and Evelyne Jacqz-Aigrain
    Drug Metabolism and Disposition November 2005, 33 (11) 1603-1607; DOI: https://doi.org/10.1124/dmd.105.005611

Articles

  • You have access
    DECREASE IN SERUM THYROXINE LEVEL BY PHENOBARBITAL IN RATS IS NOT NECESSARILY DEPENDENT ON INCREASE IN HEPATIC UDP-GLUCURONOSYLTRANSFERASE
    Yoshihisa Kato, Hiroshi Suzuki, Shinichi Ikushiro, Shizuo Yamada and Masakuni Degawa
    Drug Metabolism and Disposition November 2005, 33 (11) 1608-1612; DOI: https://doi.org/10.1124/dmd.105.005744
  • You have access
    CHARACTERIZATION OF RAT SMALL INTESTINAL AND COLON PRECISION-CUT SLICES AS AN IN VITRO SYSTEM FOR DRUG METABOLISM AND INDUCTION STUDIES
    Esther G. van de Kerkhof, Inge A. M. de Graaf, Marina H. de Jager, Dirk K. F. Meijer and Geny M. M. Groothuis
    Drug Metabolism and Disposition November 2005, 33 (11) 1613-1620; DOI: https://doi.org/10.1124/dmd.105.005686
  • You have access
    ALTERED AZT (3′-AZIDO-3′-DEOXYTHYMIDINE) GLUCURONIDATION KINETICS IN LIVER MICROSOMES AS AN EXPLANATION FOR UNDERPREDICTION OF IN VIVO CLEARANCE: COMPARISON TO HEPATOCYTES AND EFFECT OF INCUBATION ENVIRONMENT
    Juntyma J. Engtrakul, Robert S. Foti, Timothy J. Strelevitz and Michael B. Fisher
    Drug Metabolism and Disposition November 2005, 33 (11) 1621-1627; DOI: https://doi.org/10.1124/dmd.105.005058
  • You have access
    IN VITRO METABOLISM OF THE CALMODULIN ANTAGONIST DY-9760e (3-[2-[4-(3-CHLORO-2-METHYLPHENYL)-1-PIPERAZINYL]ETHYL]-5,6-DIMETHOXY-1-(4-IMIDAZOLYLMETHYL)-1H-INDAZOLE DIHYDROCHLORIDE 3.5 HYDRATE) BY HUMAN LIVER MICROSOMES: INVOLVEMENT OF CYTOCHROMES P450 IN ATYPICAL KINETICS AND POTENTIAL DRUG INTERACTIONS
    Shuko Tachibana, Yuko Fujimaki, Hiroyuki Yokoyama, Osamu Okazaki and Ken-ichi Sudo
    Drug Metabolism and Disposition November 2005, 33 (11) 1628-1636; DOI: https://doi.org/10.1124/dmd.105.004903
  • You have access
    AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS
    Anthony Atkinson, Jane R. Kenny and Ken Grime
    Drug Metabolism and Disposition November 2005, 33 (11) 1637-1647; DOI: https://doi.org/10.1124/dmd.105.005579
  • You have access
    METABOLISM OF MYOSMINE IN WISTAR RATS
    Wolfgang Zwickenpflug, Stefan Tyroller and Elmar Richter
    Drug Metabolism and Disposition November 2005, 33 (11) 1648-1656; DOI: https://doi.org/10.1124/dmd.104.003087
  • You have access
    IMPORTANCE OF CYP2D3 IN POLYMORPHISM OF DIAZEPAM P-HYDROXYLATION IN RATS
    Noriaki Sakai, Konomu Saito, Hyung-Sub Kim, Akio Kazusaka, Mayumi Ishizuka, Yoshihiko Funae and Shoichi Fujita
    Drug Metabolism and Disposition November 2005, 33 (11) 1657-1660; DOI: https://doi.org/10.1124/dmd.105.004242
  • You have access
    THE DECREASE IN LEVEL OF SERUM THYROXINE BY 2,2′,4,5,5′-PENTACHLOROBIPHENYL IN RATS AND MICE: NO CORRELATION WITH FORMATION OF METHYLSULFONYL METABOLITES
    Yoshihisa Kato, Koichi Haraguchi, Tomoaki Yamazaki, Ryohei Kimura, Nobuyuki Koga, Shizuo Yamada and Masakuni Degawa
    Drug Metabolism and Disposition November 2005, 33 (11) 1661-1665; DOI: https://doi.org/10.1124/dmd.105.006189
  • You have access
    FLAVONOIDS AS A NOVEL CLASS OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP1B1 (OATP-C) MODULATORS
    Xiaodong Wang, Allan W. Wolkoff and Marilyn E. Morris
    Drug Metabolism and Disposition November 2005, 33 (11) 1666-1672; DOI: https://doi.org/10.1124/dmd.105.005926
  • You have access
    FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF α-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS
    Sung Yeon Kim, Y. R. Santosh Laxmi, Naomi Suzuki, Kenichiro Ogura, Tadashi Watabe, Michael W. Duffel and Shinya Shibutani
    Drug Metabolism and Disposition November 2005, 33 (11) 1673-1678; DOI: https://doi.org/10.1124/dmd.105.005330
  • You have access
    FUNCTIONAL ASSESSMENT OF MULTIPLE P-GLYCOPROTEIN (P-GP) PROBE SUBSTRATES: INFLUENCE OF CELL LINE AND MODULATOR CONCENTRATION ON P-GP ACTIVITY
    Mitchell E. Taub, Lalitha Podila, Diane Ely and Iliana Almeida
    Drug Metabolism and Disposition November 2005, 33 (11) 1679-1687; DOI: https://doi.org/10.1124/dmd.105.005421
  • You have access
    BIOTRANSFORMATION OF A GABAA RECEPTOR PARTIAL AGONIST IN SPRAGUE-DAWLEY RATS AND CYNOMOLGUS MONKEYS: IDENTIFICATION OF TWO UNIQUE N-CARBAMOYL METABOLITES
    Christopher L. Shaffer, Mithat Gunduz, Thomas N. O'Connell, R. Scott Obach and Shiyin Yee
    Drug Metabolism and Disposition November 2005, 33 (11) 1688-1699; DOI: https://doi.org/10.1124/dmd.105.004630
  • You have access
    PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES
    Dermot F. McGinnity, James Tucker, Steve Trigg and Robert J. Riley
    Drug Metabolism and Disposition November 2005, 33 (11) 1700-1707; DOI: https://doi.org/10.1124/dmd.105.005884
  • You have access
    BIOTRANSFORMATION OF DERAMCICLANE IN PRIMARY HEPATOCYTES OF RAT, MOUSE, RABBIT, DOG, AND HUMAN
    Katalin Monostory, Krisztina Kőhalmy, Krisztina Ludányi, Gábor Czira, Sándor Holly, László Vereczkey, Iván Ürmös, Imre Klebovich and László Kóbori
    Drug Metabolism and Disposition November 2005, 33 (11) 1708-1716; DOI: https://doi.org/10.1124/dmd.105.003764
  • You have access
    ROLE OF CYP2E1 IN DERAMCICLANE METABOLISM
    Katalin Monostory, Krisztina Köhalmy, Eszter Hazai, László Vereczkey and László Kóbori
    Drug Metabolism and Disposition November 2005, 33 (11) 1717-1722; DOI: https://doi.org/10.1124/dmd.105.003772
  • You have access
    RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB
    Vinita Uttamsingh, Chuang Lu, Gerald Miwa and Liang-Shang Gan
    Drug Metabolism and Disposition November 2005, 33 (11) 1723-1728; DOI: https://doi.org/10.1124/dmd.105.005710
  • You have access
    IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION
    Donglu Zhang, Theodore J. Chando, Donald W. Everett, Christopher J. Patten, Shangara S. Dehal and W. Griffith Humphreys
    Drug Metabolism and Disposition November 2005, 33 (11) 1729-1739; DOI: https://doi.org/10.1124/dmd.105.005447
  • You have access
    HEPATIC, EXTRAHEPATIC, MICROSOMAL, AND MITOCHONDRIAL ACTIVATION OF THE N-HYDROXYLATED PRODRUGS BENZAMIDOXIME, GUANOXABENZ, AND RO 48-3656 ([[1-[(2S)-2-[[4-[(HYDROXYAMINO)IMINOMETHYL]BENZOYL]AMINO]-1-OXOPROPYL]-4-PIPERIDINYL]OXY]-ACETIC ACID)
    Bernd Clement, Sabine Mau, Stephanie Deters and Antje Havemeyer
    Drug Metabolism and Disposition November 2005, 33 (11) 1740-1747; DOI: https://doi.org/10.1124/dmd.105.005249
  • You have access
    QUANTITATION OF BISPHENOL A AND BISPHENOL A GLUCURONIDE IN BIOLOGICAL SAMPLES BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY
    Wolfgang Völkel, Nataly Bittner and Wolfgang Dekant
    Drug Metabolism and Disposition November 2005, 33 (11) 1748-1757; DOI: https://doi.org/10.1124/dmd.105.005454
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition: 33 (11)
Drug Metabolism and Disposition
Vol. 33, Issue 11
1 Nov 2005
  • Table of Contents
  • About the Cover
  • Index by author
Sign up for alerts

Jump to

  • Commentary
  • Short Communications
  • Articles
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics